Larvol Delta - Elevar-Therapeutics-CEO-Kim-Donggun-July-approval-expected-for-rstline-liver-cancer-drug-with-no-outstanding-review-issues

AiTan (rivoceranib) - Elevar Therapeutics

AiRuiKa (camrelizumab) - Elevar Therapeutics

https://www.thebionews.net/news/articleView.html?idxno=25535

Jun 16, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next